Tags : Almirall

PharmaShots Weekly Snapshot (February 03-07, 2020)

WHO to Accelerate Global Research and Innovation Against Corona Virus Published: Feb 06, 2020 | Tags: WHO, Accelerate, Global, Research, Innovation, Against, Corona Virus 2.  Curis Amends its Existing Collaboration with Aurigene for the Development and Commercialization of CA-170 Published: Feb 07, 2020 | Tags: Curis, Amends, Existing Collaboration, Aurigene, Development, Commercialization, CA-170 3.  Novo […]Read More

PharmaShots Weekly Snapshot (January 06-10, 2020)

Nektar Therapeutics Signs a Clinical Trial Collaboration with Bristol-Myers Squibb Published: Jan 10, 2020 | Tags: Nektar Therapeutics, Signs, Clinical Trial, Collaboration, Bristol-Myers Squibb 2. Eli Lilly to Acquire Dermira for $1.1B Published: Jan 10, 2020 | Tags: Eli Lilly, Acquire, Dermira, $1.1B 3. Bayer Signs a Three Year Multi Target AI-based Agreement with Exscientia to Treat […]Read More

PharmaShots Weekly Snapshot (December 09-13, 2019)

1.  Pfizer’s Amsparity (biosimilar, adalimumab) Receives CHMP’s Positive Opinion for Inflammatory and Autoimmune Disorders Published: Dec 12, 2019 | Tags: Pfizer, Amsparity, biosimilar, adalimumab, Receives, CHMP, Positive Opinion, Inflammatory, Autoimmune Disorders 2.  Janssen’s Darzalex (daratumumab) Combination Regimen Receives CHMP’s Positive Opinion for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma Published: Dec 13, 2019 | […]Read More

Almirall to Accelerate Drug Discovery Process Utilizing Iktos’ AI Technology

Shots: Almirall will leverage Iktos’s generative modeling AI technology for compound optimization and accelerating the identification of drug candidates for its drug discovery program The collaboration will provide an opportunity to Almirall to combine its expertise with Iktos’ AI precision and celerity to improve QoL Iktos’ AI technology is based on deep generative models helps […]Read More

NICE Publishes Final Recommendation for Almirall’s Ilumetri (tildrakizumab) to Treat

Shots: NICE has recommended Ilumetri (tildrakizumab) as a cost-effective option for the treatment of adults patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy following its assessment submission in Aug’18 Ilumetri (tildrakizumab) is evaluated in P-III reSURFACE 1 and 2 study in 1,800 patients > 200 sites across the globe resulted in maintaining […]Read More

Almirall Signs a Research Collaboration with HitGen for its DNA-Encoded

Shots: HitGen to receive upfront & milestones from Almirall to develop novel small molecules for Almirall’s target The focus of the collaboration is to utilize HitGen’s technology based on DNA-encoded library design, synthesis and screening, in identifying small molecules for the treatment of atopic dermatitis HitGen’s DELs is a drug discovery platform including 400B macrocyclic […]Read More